GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » Net Income

Akili (AKLI) Net Income : $-59.49 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Akili Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Akili's Net Income for the three months ended in Dec. 2023 was $-11.15 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-59.49 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Akili's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.14.


Akili Net Income Historical Data

The historical data trend for Akili's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili Net Income Chart

Akili Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
-20.63 -25.65 -61.35 -7.96 -59.49

Akili Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.82 -20.71 -11.76 -15.88 -11.15

Akili Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Akili's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-59.44+-0.053+0+-7.105427357601E-15
=-59.49

Akili's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-11.094+-0.053+0+0
=-11.15

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akili  (NAS:AKLI) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Akili's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Akili Net Income Related Terms

Thank you for viewing the detailed overview of Akili's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Akili (AKLI) Business Description

Traded in Other Exchanges
Address
125 Broad Street, Fifth Floor, Boston, MA, USA, 02110
Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.
Executives
Jacqueline Studer officer: Chief Legal Officer IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin officer: See Remarks AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii director, officer: Chief Executive Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag officer: Chief Financial Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya director, 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges director C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina officer: Chief Medical Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David officer: Chief Product Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110